Analytical Data
-
Gene name
MON1A
- Application
-
Alternative Names
FLJ97088; MGC13272; MON1 homolog A; MON1A; MON1A_HUMAN; SAND1; Vacuolar fusion protein MON1 homolog A
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q86VX9
-
Expression Region
205-555aa
-
Molecular Weight
56.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MON1A, a member of the MON1-CCZ1 complex, plays a vital role in the regulation of endosomal trafficking and membrane fusion processes, which are essential for various cellular functions, including receptor recycling and lysosomal biogenesis. Research has illuminated its significance in the context of cellular homeostasis and its implications in human diseases, particularly neurodegenerative disorders and cancer. The protein is believed to facilitate the transition between early and late endosomes, guiding the appropriate sorting and degradation of intracellular cargo. Disruptions in MON1A function can lead to impaired cellular signaling and contribute to pathologies, making it a potential biomarker and therapeutic target. In recent studies, recombinant MON1A protein has been produced to investigate its mechanism of action and to understand its interactions with other trafficking proteins. The ability to generate and manipulate MON1A as a recombinant protein allows for detailed structural and functional analyses, providing insights into its role in cellular processes. Understanding MON1A's biochemical properties and its interactions with other cellular components is crucial for developing targeted therapies aimed at correcting the dysregulation observed in various diseases. As such, ongoing research is focused on elucidating the pathways influenced by MON1A and the potential therapeutic applications that could arise from modulating its activity.
